These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 19663772)

  • 1. Restoring p53 function in cancer: novel therapeutic approaches for applying the brakes to tumorigenesis.
    Di Cintio A; Di Gennaro E; Budillon A
    Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):1-13. PubMed ID: 19663772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy.
    Liu Y; Wang X; Wang G; Yang Y; Yuan Y; Ouyang L
    Eur J Med Chem; 2019 Aug; 176():92-104. PubMed ID: 31100649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment.
    Gupta A; Shah K; Oza MJ; Behl T
    Biomed Pharmacother; 2019 Jan; 109():484-492. PubMed ID: 30551517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation.
    Meulmeester E; Pereg Y; Shiloh Y; Jochemsen AG
    Cell Cycle; 2005 Sep; 4(9):1166-70. PubMed ID: 16082221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach.
    Di J; Zhang Y; Zheng J
    Curr Cancer Drug Targets; 2011 Oct; 11(8):987-94. PubMed ID: 21762075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The regulation of MDM2 by multisite phosphorylation--opportunities for molecular-based intervention to target tumours?
    Meek DW; Hupp TR
    Semin Cancer Biol; 2010 Feb; 20(1):19-28. PubMed ID: 19897041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
    Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
    Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
    Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
    J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination.
    Wei J; Yang Y; Lu M; Xu L; Liu F; Yuan Z; Bao Q; Jiang Z; Xu X; Guo X; Zhang X; You Q; Sun H
    Anticancer Agents Med Chem; 2015; 16(2):174-89. PubMed ID: 26343143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?
    Wade M; Wahl GM
    Mol Cancer Res; 2009 Jan; 7(1):1-11. PubMed ID: 19147532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of p53 in cancer drug resistance and targeted chemotherapy.
    Hientz K; Mohr A; Bhakta-Guha D; Efferth T
    Oncotarget; 2017 Jan; 8(5):8921-8946. PubMed ID: 27888811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
    Hu B; Gilkes DM; Chen J
    Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of MDM2 and MDMX: a structural perspective.
    Riedinger C; McDonnell JM
    Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
    Toledo F; Wahl GM
    Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.
    Jones RJ; Bjorklund CC; Baladandayuthapani V; Kuhn DJ; Orlowski RZ
    Mol Cancer Ther; 2012 Oct; 11(10):2243-53. PubMed ID: 22933706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
    Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
    J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
    Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
    Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
    Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
    Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
    Ghosh M; Huang K; Berberich SJ
    Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Murine double minute 2 siRNA and wild-type p53 gene therapy interact positively with zinc on prostate tumours in vitro and in vivo.
    Gu J; Wang B; Liu Y; Zhong L; Tang Y; Guo H; Jiang T; Wang L; Li Y; Cai L
    Eur J Cancer; 2014 Apr; 50(6):1184-94. PubMed ID: 24447832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.